Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...

Gilead Sciences, Inc. GILD, one of the top biotech companies, has put up a robust performance so far in 2025. Shares of the company have surged 26.5% year to date compared with the industry’s growth ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best affordable healthcare stocks to buy now. Gilead Sciences, Inc. (NASDAQ:GILD) announced on December 22 that it has exercised its combined option ...

$GILD insiders have traded $GILD stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales. We have seen ...

Generally speaking, I’m not a big fan of discussing biopharmaceutical firms such as Gilead Sciences (NASDAQ:GILD). While the sector is intriguing and offers bountiful opportunities, it’s also replete ...

Regeneron Pharmaceuticals stock increased by 19% over the past month driven by strong third-quarter earnings and robust sales of its flagship drugs, Dupixent (for eczema and other inflammatory ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the September 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per ...

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Gilead Sciences, Inc. is one of them. Gilead Sciences, Inc. (NASDAQ:GILD), headquartered in Foster City, ...